» Articles » PMID: 35340797

Impact of Early Treatment With High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children

Overview
Date 2022 Mar 28
PMID 35340797
Authors
Affiliations
Soon will be listed here.
Abstract

Kawasaki disease (KD) occurs in five-year-old or younger children. This study aimed to evaluate the impact of high-dose intravenous immunoglobulin plus acetylsalicylic acid therapy on the prevention and treatment of coronary artery lesions and to evaluate the impact of high-dose acetylsalicylic acid (ASA) on the hearing of the patients. In this retrospective cohort study, 31 patients with KD were followed from January 2012 to December 2015. The clinical, para-clinical, color Doppler echocardiogram and audiometry results were evaluated. Overall, seven cases (22.6%) developed coronary artery aneurysm (CAA) in the acute phase of the disease, of whom only two still had CAA at the end of the treatment (6%). One of the five children with CAA recovery had a delay in the onset of treatment and one of two patients with persistent CAA at the end of treatment was admitted within the first 10 days. There was no evidence-based abnormal liver biochemical test. None of the patients developed sensorineural hearing loss (SNHL) on audiometry tests conducted before and after treatment. Recovery of coronary artery lesions was 71.43% after 28 days of the onset of treatment. The distribution of coronary artery aneurysm was not different in terms of the time of the treatment initiation (P-Value = 0.371). None of the children had a sensorineural hearing loss (SNHL) 48 hours and 4 weeks after treatment.

Citing Articles

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis.

Li Z, Cai J, Lu J, Wang M, Yang C, Zeng Z Ital J Pediatr. 2023; 49(1):45.

PMID: 37038188 PMC: 10088291. DOI: 10.1186/s13052-023-01451-6.

References
1.
Newburger J, Takahashi M, Gerber M, Gewitz M, Tani L, Burns J . Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart.... Circulation. 2004; 110(17):2747-71. DOI: 10.1161/01.CIR.0000145143.19711.78. View

2.
Lee B, Tay J, Yip W, Yap H, Chan K, Low P . Kawasaki syndrome in Chinese children. Ann Trop Paediatr. 1989; 9(3):147-51. DOI: 10.1080/02724936.1989.11748618. View

3.
Zhu B, Lv H, Sun L, Zhang J, Cao L, Jia H . A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2011; 171(3):571-8. PMC: 3284666. DOI: 10.1007/s00431-011-1585-4. View

4.
Day R, Graham G, Bieri D, Brown M, Cairns D, Harris G . Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol. 1989; 28(6):695-702. PMC: 1380040. DOI: 10.1111/j.1365-2125.1989.tb03562.x. View

5.
Magalhaes C, Magalhaes Alves N, Oliveira K, Silva I, Gandolfi L, Pratesi R . Sensorineural hearing loss: an underdiagnosed complication of Kawasaki disease. J Clin Rheumatol. 2010; 16(7):322-5. DOI: 10.1097/RHU.0b013e3181f603bc. View